EVGN Key Statistics, Chart & Performance
The current stock price of EVGN is 1.11 USD. In the past month the price increased by 0.91%. In the past year, price decreased by -29.3%.
EVGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About EVGN
Company Profile
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Company Info
EVOGENE LTD
13 Gad Feinstein Street, Park Rehovot
Rehovot 7414002 IL
CEO: Ofer Haviv
Employees: 117
Phone: 97289311900
EVOGENE LTD / EVGN FAQ
Can you describe the business of EVOGENE LTD?
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Can you provide the latest stock price for EVOGENE LTD?
The current stock price of EVGN is 1.11 USD. The price increased by 0.45% in the last trading session.
Does EVOGENE LTD pay dividends?
EVGN does not pay a dividend.
How is the ChartMill rating for EVOGENE LTD?
EVGN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for EVGN stock?
EVOGENE LTD (EVGN) currently has 117 employees.
When does EVOGENE LTD (EVGN) report earnings?
EVOGENE LTD (EVGN) will report earnings on 2026-03-04, before the market open.
Can you provide the ownership details for EVGN stock?
You can find the ownership structure of EVOGENE LTD (EVGN) on the Ownership tab.
EVGN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EVGN. When comparing the yearly performance of all stocks, EVGN is a bad performer in the overall market: 86.81% of all stocks are doing better.
EVGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVGN. EVGN has a bad profitability rating. Also its financial health evaluation is rather negative.
EVGN Financial Highlights
Over the last trailing twelve months EVGN reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 88.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.54% | ||
| ROE | -240.72% | ||
| Debt/Equity | 1.62 |
EVGN Forecast & Estimates
7 analysts have analysed EVGN and the average price target is 2.55 USD. This implies a price increase of 129.73% is expected in the next year compared to the current price of 1.11.
For the next year, analysts expect an EPS growth of 79.67% and a revenue growth -56.03% for EVGN